Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride injection for prevention of postoperative nausea and vomiting
ChiCTR2300072459Phase 3Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Amisulpride group with Placebo group (2 arms). Primary endpoint: Nausea rating scale. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2300072459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072459.